Dose-dependent circulating immunoglobulin A antibody-secreting cell and serum antibody responses in Swedish volunteers to an oral inactivated enterotoxigenic Escherichia coli vaccine
- PMID: 11238232
- PMCID: PMC96073
- DOI: 10.1128/CDLI.8.2.424-428.2001
Dose-dependent circulating immunoglobulin A antibody-secreting cell and serum antibody responses in Swedish volunteers to an oral inactivated enterotoxigenic Escherichia coli vaccine
Abstract
The immunogenicity of different preparations of an oral inactivated enterotoxigenic Escherichia coli (ETEC) vaccine was evaluated in Swedish volunteers previously unexposed to ETEC infection. The vaccine preparations consisted of recombinant cholera toxin B subunit (CTB) and various amounts of formalin-killed whole bacteria expressing the most prevalent colonization factor antigens (CFAs). Significant immunoglobulin A (IgA) antibody-secreting cell (ASC) responses against CTB and the various CFA components were seen in a majority of volunteers after two doses of ETEC vaccine independent of the vaccine lot given. The IgA ASC responses against CTB were significantly higher after the second than after the first immunization, whereas the CFA-specific IgA ASC responses were almost comparable after the first and second doses of ETEC vaccine. Two immunizations with one-third of a full dose of CFA-ETEC bacteria induced lower frequencies of IgA ASC responses against all the different CFAs than two full vaccine doses, i.e., 63 versus 80% for CFA/I, 56 versus 70% for CS1, 31 versus 65% for CS2, and 56 versus 75% for CS4. The proportion of vaccinees responding with rises in the titer of serum IgA antibody against the various CFA antigens was also lower after immunization with the reduced dose of CFA-ETEC bacteria. These findings suggest that measurements of circulating IgA ASCs can be used not only for qualitative but also for quantitative assessments of the immunogenicity of individual fimbrial antigens in various preparations of ETEC vaccine.
Figures

Similar articles
-
Development and preclinical evaluation of safety and immunogenicity of an oral ETEC vaccine containing inactivated E. coli bacteria overexpressing colonization factors CFA/I, CS3, CS5 and CS6 combined with a hybrid LT/CT B subunit antigen, administered alone and together with dmLT adjuvant.Vaccine. 2013 May 7;31(20):2457-64. doi: 10.1016/j.vaccine.2013.03.027. Epub 2013 Mar 27. Vaccine. 2013. PMID: 23541621
-
Clinical trial to evaluate safety and immunogenicity of an oral inactivated enterotoxigenic Escherichia coli prototype vaccine containing CFA/I overexpressing bacteria and recombinantly produced LTB/CTB hybrid protein.Vaccine. 2013 Feb 6;31(8):1163-70. doi: 10.1016/j.vaccine.2012.12.063. Epub 2013 Jan 7. Vaccine. 2013. PMID: 23306362 Clinical Trial.
-
Antibody-secreting cells in human peripheral blood after oral immunization with an inactivated enterotoxigenic Escherichia coli vaccine.Infect Immun. 1992 Jul;60(7):2605-11. doi: 10.1128/iai.60.7.2605-2611.1992. Infect Immun. 1992. PMID: 1612730 Free PMC article.
-
Strategies to overexpress enterotoxigenic Escherichia coli (ETEC) colonization factors for the construction of oral whole-cell inactivated ETEC vaccine candidates.Appl Microbiol Biotechnol. 2012 Mar;93(6):2291-300. doi: 10.1007/s00253-012-3930-6. Epub 2012 Feb 16. Appl Microbiol Biotechnol. 2012. PMID: 22350259 Review.
-
Vaccines for enterotoxigenic Escherichia coli: current status.Curr Opin Gastroenterol. 2005 Jan;21(1):15-9. Curr Opin Gastroenterol. 2005. PMID: 15687879 Review.
Cited by
-
Comparative safety and immunogenicity of two attenuated enterotoxigenic Escherichia coli vaccine strains in healthy adults.Infect Immun. 2006 Feb;74(2):994-1000. doi: 10.1128/IAI.74.2.994-1000.2006. Infect Immun. 2006. PMID: 16428745 Free PMC article. Clinical Trial.
-
Evaluation of the safety and immunogenicity of the oral inactivated multivalent enterotoxigenic Escherichia coli vaccine ETVAX in Bangladeshi adults in a double-blind, randomized, placebo-controlled Phase I trial using electrochemiluminescence and ELISA assays for immunogenicity analyses.Vaccine. 2019 Sep 3;37(37):5645-5656. doi: 10.1016/j.vaccine.2018.11.040. Epub 2018 Nov 22. Vaccine. 2019. PMID: 30473185 Free PMC article. Clinical Trial.
-
Safety and immunogenicity of a prototype enterotoxigenic Escherichia coli vaccine administered transcutaneously.Infect Immun. 2002 Apr;70(4):1874-80. doi: 10.1128/IAI.70.4.1874-1880.2002. Infect Immun. 2002. PMID: 11895950 Free PMC article.
-
Vaccines for preventing enterotoxigenic Escherichia coli (ETEC) diarrhoea.Cochrane Database Syst Rev. 2013 Jul 5;2013(7):CD009029. doi: 10.1002/14651858.CD009029.pub2. Cochrane Database Syst Rev. 2013. PMID: 23828581 Free PMC article.
-
From cholera to enterotoxigenic Escherichia coli (ETEC) vaccine development.Indian J Med Res. 2011 Feb;133(2):188-96. Indian J Med Res. 2011. PMID: 21415493 Free PMC article. Review.
References
-
- Åhrén C, Wennerås C, Holmgren J, Svennerholm A-M. Intestinal antibody response after oral immunization with a prototype cholera B subunit-colonization factor antigen enterotoxigenic Escherichia coli vaccine. Vaccine. 1993;11:929–934. - PubMed
-
- Black R E. The epidemiology of diarrheal disease: implications for control by vaccines. Vaccine. 1993;11:100–106. - PubMed
-
- Clemens J D, Sack D A, Harris J R, Chakraborty J, Neogy P K, Stanton B, Huda N, Khan M U, Kay B A, Khan M R, Ansaruzzaman M, Yunus M, Rao M R, Svennerholm A-M, Holmgren J. Cross-protection by B subunit-whole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: results of a large-scale field trial. J Infect Dis. 1988;158:372–377. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous